Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-05-31
2005-05-31
Achutamurthy, Ponnathapura (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S212000, C435S225000
Reexamination Certificate
active
06899876
ABSTRACT:
Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
REFERENCES:
patent: 5084007 (1992-01-01), Malin et al.
patent: 5491169 (1996-02-01), Roques et al.
patent: 5816259 (1998-10-01), Rose
patent: 6251391 (2001-06-01), Wilkinson et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6447772 (2002-09-01), Houston
patent: 2002/0041871 (2002-04-01), Brudnak
“The Safety of Enzymes Derived from Aspergillus”National Enzyme Company, 1997.
Ackerman, L., “Discussion of Autism General Information” (1997).
Cade, Robert et al., “Autism and Schizophrenia: Intestinal Disorders” Abstract, Departments of Medicine, Physiology and Psychology, University of Florida, (1997).
Chich, Jean-Francois. 136. X-Pro dipeptidyl-peptidase.Handbook of Proteoytic Enzymes, Academic Press, pp. 1-3 (1998).
Chabance, B., et al., “Casein Peptide Release And Passage To The Blood In Humans During Digestion Of Milk Or Yogurt,”Biochimie80:155-165 (1998).
Fukudome, S. et al., “Opioid Peptides Derived From Wheat Gluten: Their Isolation And Characterization,”F.E.B.S., 296(1):107-111 (1992).
Kitozono, Ana et al. 139. Prolyl aminopeptidase.Handbook of Proteoytic Enzymes, pp. 412-413, (1998).
Kozakova, H., et al., “Brush Border Enzyme Activities In The Small Intestine After Long-Term Gliadin Feeding In Animal Models Of Human Coeliac Disease,”Folia Microbiol. (Praha) 43(5):497-500 (1998) (Abstract).
Kreil, G., et al., “Studies On The Enzymatic Degradation Of Beta-Casomorphins,”Life Sci. 33 Suppl 1:137-40 (1983) (Abstract).
Krepela E., et al., “Demonstration Of Two Molecular Forms Of Dipeptidyl Peptidase IV In Normal Human Serum,”Physiol. Bohemoslov32(6):486-96 (1983) (Abstract).
McDonald, J. Ken. 138. Dipeptidyl-peptidase II.Handbook of Proteotyic Enzymes, pp. 408-411, (1998).
The Merck Manual of Medical Information, Robert Berkow, et al., eds “Seizure Disorders,” pp. 376-381, (1997).
The Merck Manual of Medical Information, Robert Berkow, et al., eds., “Childhood Schizophrenia,” pp. 1436-1437, (1997).
The Merck Manual of Medical Information, Robert Berkow, et al., eds., “Schizophrenia and Delusional Disorder,” pp. 475-479, (1997).
The Merck Manual of Medical Information, Robert Berkow, et al., eds., “Attention Deficit Disorder,” pp. 1365-1367, (1997).
The Merck Manual of Medical Information, Robert Berkow, et al. eds., “Autism,” pp. 1434-1435, (1997).
Misumi, Yoshio and Ikehara, Yukio. 129. Dipeptidyl-pepetidases A and B.Handbook of Proteoytic Enzymes, pp. 382-383, (1998).
Reichelt, L. Karl, et al., “Nature And Consequences Of Hyperpeptiduria And Bovine Casomorphins Found In Autisic Syndromes,”Brain Dysfunct7:71-85 (1994).
Reichelt, L. Karl, et al., “Probable Etiology and Possible Treatment of Childhood Autism,”Brain Dysfunct4:308-319 (1991).
Reichelt, L. Karl, et al., “Gluten, Milk Proteins And Autism: Dietary Intervention Effects On Behavior And Peptide Secretion,”J. Applied Nutrition42(1):1-11 (1990).
Seroussi, K., “Frequently Asked Questions about Dietary Intervention for the Treatment of Autism” (1995), www.enabling.org/ia/celiac/aut/autgffaq.html.
Sjostrom, H. et al., “Intestinal Peptidases And Sucrase In Celiac Disease,”Clin. Chim. Acta. 109(1):53-8 (1981) (Abstract).
Sun, Z., et al., “A Peptide Found In Schizophrenia And Autism Causes Behavioral Changes In Rats,”Autism3(1):85-95 (1999).
Sun, Z., et al., “B-casomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism”Autism3(1) 67-83, (1999).
Takahashi, K., “The Specificity Of Peptide Bond Cleavage Of Acid Proteinase A From Aspergillus Niger Var. Macrosporus Toward Oxidized Ribonuclease A,”Biosci. Biotech. Biochem., 61(2):381-383 (1997).
Takahashi, K., et al., “Structure and Function of Pepstatin-Insenstive Acid Proteinase FromAspergillus Nigervar.Macrosporus” Structure and Function of the Aspartic Proteinases, B.M. Dunn, ed., Plenum Press, New York, pp. 203-211, (1991).
Whitely, P., et al., “A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings,”Autism3(1) 45-65, (1999).
Wilk, Sherwin, 525. Pro-X dipeptidase.Handbook of Proteoytic Enzymes, p. 1517, (1998).
Achutamurthy Ponnathapura
Graybeal Jackson Haley LLP
Moore William W.
ProThera, Inc.
LandOfFree
Compositions and methods relating to reduction of symptoms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods relating to reduction of symptoms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods relating to reduction of symptoms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388525